GeoVax Labs (NASDAQ:GOVX) Price Target Raised to $10.00

GeoVax Labs (NASDAQ:GOVX) had its price target upped by Noble Financial from $6.00 to $10.00 in a research note published on Monday, Benzinga reports. They currently have an outperform rating on the stock. Noble Financial also issued estimates for GeoVax Labs’ Q3 2024 earnings at ($1.61) EPS and Q4 2024 earnings at ($1.74) EPS.

Several other analysts also recently commented on GOVX. Roth Mkm initiated coverage on shares of GeoVax Labs in a report on Tuesday, July 16th. They set a buy rating and a $20.00 target price for the company. Roth Capital raised shares of GeoVax Labs to a strong-buy rating in a report on Tuesday, July 16th. HC Wainwright reaffirmed a buy rating and set a $8.00 target price on shares of GeoVax Labs in a report on Monday, August 12th. Finally, EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a strong-buy rating in a report on Tuesday, July 23rd. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $12.67.

GeoVax Labs Stock Performance

GeoVax Labs stock opened at $8.35 on Monday. The company’s 50-day moving average is $2.84 and its 200-day moving average is $2.24. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.57) by $0.58. The firm had revenue of $0.30 million for the quarter. During the same quarter in the previous year, the company earned ($3.30) EPS. As a group, research analysts predict that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC acquired a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is owned by institutional investors and hedge funds.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.